

Message

From: Abbott, Christopher J. EOP/WHO [REDACTED]
Sent: 5/19/2020 7:11:26 PM
To: Taber, Terry [Terry] R [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5c93fe2be24b4a8dab6fec329c126688-L118545]
CC: Continenza, James V [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=18c7c27de2c9473abbe71ea1ad338b4e-10180872]
Subject: RE: Kodak Pharma Manufacturing

NOTICE: External eMail. NEVER enter passwords. Only click links if you know the sender and content are safe.

Terry,


Thanks for the note. Glad to hear you are able to produce ketamine starting materials. Can you please send a proposal of what you would actually need from the USG to support your efforts?

We are really focused on the long-term issues here, so we are not really looking at funding material inputs here, but are there capital investments or things of that nature that could help you all become cost competitive in the long-run?

As far as chemicals to prioritize, we are really looking for starting materials that go into the API for the drugs on the list found on this attachment at the bottom of this

link: <https://beta.sam.gov/opp/308767cbe31f403fb95b25e12719e056/view>

Note that the list attached does include ketamine and propofol, but not etomidate.

I assume you also saw the news on  — it may be worth checking in with them to see if there are starting materials they need.

Also, do you happen to have any capability to produce nitrocellulose membrane?

Best,
Chris

Christopher Abbott
Deputy Director
Office of Trade & Manufacturing Policy
The White House
[REDACTED]

From: Taber, Terry [Terry] R [REDACTED]
Sent: Monday, May 18, 2020 2:53 PM
To: Abbott, Christopher J. EOP/WHO [REDACTED]
Cc: Continenza, James V [REDACTED]
Subject: [EXTERNAL] Kodak Pharma Manufacturing

Chris,
Thank you for the phone conversation last Wednesday.

Kodak is committed to be a US based supplier of pharmaceutical intermediates that are necessary for application to the COVID-19 crisis as well as materials required for the US

strategic manufacturing initiative and a reserve of key pharmaceuticals. Thus, my boss, Kodak Executive Chairman, Jim Continenza, wants Kodak to move fast on this important initiative and opportunity. Accordingly, Kodak has prepared an update on Ketamine, one of the key intubation drugs. As you will read in the attachment, Kodak has done previous work on a key intermediate to produce Ketamine and we have a 100 gram sample on hand for use-testing and evaluation by an Active Pharmaceutical Ingredient (API) manufacturer.

Kodak would also like to verify the intubation drugs to be part of our full proposal. Based on our call, Kodak is looking at Ketamine, Propofol, and Etomidate which are common sedative agents used during rapid sequence intubation. Please advise if this is the appropriate list as well as the list of COVID test reagents for Kodak to assess.

While we continue to work on your request, Kodak would benefit from engaging directly with specific API manufacturers in order to determine specific needs and requirements for the list of intubation drugs and test reagents. Please advise if you can provide us with your recommendation on whom we should reach out to gain additional information regarding companies manufacturing the APIs in the U.S.

Both Jim and I are always available for calls or follow-up.

Best regards,

Terry

Terry R. Taber, Ph.D.
Chief Technical Officer & VP, Kodak
SVP, Advanced Materials & Chemicals

[REDACTED]

[REDACTED] | Office: [REDACTED] | Mobile: **NPPI**

>www.kodak.com<

